AFA
NVO

Arlington Financial Advisors’s Novo Nordisk NVO Stock Holding History

Arlington Financial Advisors’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-5,152
Closed -$286K – 123
2025
Q3 		$286K Buy
+5,152
New +$302K 0.04% 96

Other funds holding NVO

Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Arlington Financial Advisors's NVO Position: Q4 2025 in Review

Arlington Financial Advisors sold out of Novo Nordisk (NVO) in Q4 2025, closing a stake of 5,152 shares — an estimated $286K sold.

Arlington Financial Advisors first reported a position in NVO in Q3 2025 and held it in 1 quarter. The position peaked at $286K in Q3 2025. 1,413 funds tracked by Wall St. Rank hold NVO as of Q4 2025.

  • Arlington Financial Advisors reported no remaining Novo Nordisk position as of Q4 2025 after selling out during the quarter.
  • Arlington Financial Advisors sold 5,152 Novo Nordisk shares in Q4 2025, an estimated $286K.
  • Arlington Financial Advisors first reported a position in Novo Nordisk in Q3 2025 and held it in 1 quarter.
  • Arlington Financial Advisors's Novo Nordisk position peaked at $286K in Q3 2025.
  • 1,413 funds tracked by Wall St. Rank held Novo Nordisk as of Q4 2025.

Based on Arlington Financial Advisors's 13F filing for Q4 2025, filed 12 Jan 2026.